RE:Reply from Fred to my email
Great email by Fred.
My take is this. The Vanderbuilt study results were compelling, and will continue to attract attention. Applying the positive effects of 4050 on a broader indiction with potential orphan patient subsets is fantastic.
Rumour I heard 6 months ago was that the Blackrock / Nantpro guys were focussed on a Diabetes related solution, perhaps there is a bigger connection... pure spec on my part. Maybe this was ultimately why mgmt made the strategic play to buy rights back ?
EAR-Regardless, :-) I think we very well may look back at this in the fairly near future and recognize this means alot more than the market is telling us. BUT the fact is right now...the market is waiting for one or more announcements that will help them make their revenue nut for Q4.